Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy

BACKGROUND. Promoter mutation in the human telomerase reverse transcriptase gene (hTERT) occurs in ~75% of primary glioblastoma (GBM). Although the mutation appears to upregulate telomerase expression and contributes to the maintenance of telomere length, its clinical significance remains unclear. M...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Main Authors: Nguyen, HuyTram N., Lie, Amy, Li, Tie, Chowdhury, Reshmi, Liu, Fei, Ozer, Byram, Wei, Bowen, Green, Richard M., Ellingson, Benjamin M., Wang, He-jing, Elashoff, Robert, Liau, Linda M., Yong, William H., Nghiemphu, Phioanh L., Cloughesy, Timothy, Lai, Albert
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2017
Assuntos:
Basic and Translational Investigations
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5464302/
https://ncbi.nlm.nih.gov/pubmed/27571882
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/now189
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares